Clinical outcome of CT-guided three-dimensional intracavitary brachytherapy combined with intensity-modulated radiotherapy for advanced cervical cancer(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2022年第10期
- Page:
- 1213-1216
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- Clinical outcome of CT-guided three-dimensional intracavitary brachytherapy combined with intensity-modulated radiotherapy for advanced cervical cancer
- Author(s):
- YANG Jie; GUO Lining; XU Bianju
- Department of Obstetrics and Gynecology, the First Hospital of Yulin, Yulin 719000, China
- Keywords:
- Keywords: cervical cancer CT-guided three-dimensional intracavitary brachytherapy intensity-modulated radiotherapy cisplatin
- PACS:
- R816.91
- DOI:
- DOI:10.3969/j.issn.1005-202X.2022.10.006
- Abstract:
- Abstract: Objective To investigate the clinical outcome in advanced cervical cancer patients treated with CT-guided three-dimensional intracavitary brachytherapy combined with intensity-modulated radiotherapy (IMRT) and cisplatin chemotherapy. Methods Among 97 advanced cervical cancer patients selected for retrospective analysis, 55 patients received CT-guided three-dimensional intracavity brachytherapy combined with IMRT and cisplatin chemotherapy (observation group), and the other 42 patients were treated with two-dimensional intracavitary brachytherapy combined with IMRT and cisplatin chemotherapy (control group). The treatment outcome, radiation damage to organs-at-risk, and 3-year prognostic outcomes were compared between two groups. Results After radiochemotherapy, the proportion of CR+PR patients in observation group was 98.18%, higher than 88.10% in control group (P<0.05). The average radiation dose and 2.0 cm3 radiation dose to the small intestine, bladder and rectum were significantly lower in observation group than in control group (P<0.05), and the incidences of myelosuppression, radiation proctitis and radiation cystitis in observation group were significantly lower than those in control group (P<0.05). After 3 years of follow-up, the survival rate in observation group was close to that of control group (P>0.05), but the 3-year median survival time in observation group was longer than that in control group (P<0.05). Conclusion CT-guided three-dimensional intracavity brachytherapy combined with IMRT and cisplatin chemotherapy is more effective than two-dimensional intracavity brachytherapy combined with IMRT and cisplatin chemotherapy, with less radiation damage to organs-at-risk and longer survival time.
Last Update: 2022-10-27